Table 2 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
Matthew T. Campbell, Amishi Y. Shah,Pavlos Msaouel,Nizar M. Tannir,Arlene O. Siefker-Radtke,Ashish M. Kamat,Neema Navai,Colin P.N. Dinney,Priya Rao,Charles C. Guo,Rahul A. Sheth, Aradhana M. Venkatesan,Rebecca S. Tidwell, Shalini S. Yadav,Aidi Gu, Hong Chen, Marc Macaluso,Fei Duan,Sreyashi Basu,Sonali Jindal,Padmanee Sharma crossref（2024）
摘要
Treatment-related adverse events in the mRCC cohort
更多查看译文
AI 理解论文
溯源树
样例
